“More Is Better” Says J&J As It Takes Up The Ebola Challenge
Johnson & Johnson has leveraged its innovation model, reached out to partners, and fast-tracked a plan to produce one million units of an in-development combination vaccine for the lethal Ebola virus.
You may also be interested in...
FDA expects few people would get the disease in the U.S., but many could receive a vaccine.
Multiple companies are receiving funding or are in discussions with federal agencies about development of rapid assays for Ebola that can be used by patients and health care workers in the field, a top official at the National Institute of Allergy and Infectious Diseases told "The Gray Sheet."
Johnson & Johnson is nearing the completion of its network of early-stage innovation centers. IN VIVO talks to Patrick Verheyen of the year-old London hub to see where innovation centers fit into the J&J plan, and to Jimmy Zhang of the company’s soon-to-launch Shanghai branch about the climate for innovation in China and the wider Asia-Pacific region.